Thomas Castles

Collecting online search queries could help scientists study adverse health events stemming from illicit substance use.

Telemedicine is more than just a trend in medicine – it's one of the most potent tools available to health systems and patients alike.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

In response to patient concerns about dosing options and duration of effect, researchers at Shire Pharmaceuticals created Mydayis for the treatment of ADHD symptoms.

Psychedelics like psilocybin have been receiving attention from psychiatrists on and off for decades. Here's what we've learned, and what's on the horizon.

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Patients struggling with addiction can be difficult to treat. Following best practices can help simplify a complex process.

The drug showed improved symptoms across multiple doses in a 6-month study.

Doris Greenberg, MD, discusses the fine line between Asperger's Syndrome and Autism Spectrum Disorder.

Patients treated with C3F8 saw a superlative 84% release rate, according to study authors.

It's been a busy week in the world of public and private health care. Here's everything you need to know to stay connected.

Plus a "Better Care Reconciliation Act" wrap up and 2 bonus approvals from across the pond.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

Novo Nordisk seeks broad primary prevention claim, EMDAC recommends drug for patients with established CV.

Glioma is less common among diabetes patients.

Isentress HD (raltegravir) is a new dosage of previously approved treatment.

Michael Wechsler, MD, MMSc, recounts the phase III trial of Mepolizumab on patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Eli Lilly drug reduces migraines by 4 to 5 days per month.

$1 million is up for grabs

Babies exposed to marijuana in the womb may require clinical care sooner.

Tablets are approved in several dose types

Abaloparatide reduces bone fractures, but raises tumor concerns.

Praluent can help patients with clinical ASCVD or HeFH